MCOLN2 and glioblastoma: We found that the loss of both TRPML2 and TRPML1 channels (TRPML2neg TRPML1neg GBM subgroup) was associated with the worst prognosis (OS 3 months), followed by the loss of TRPML1 expression in high-TRPML2-expressing GBM patients (TRPML2high TRPML1neg (OS 7 months)).